摘要：Declining public trust in science and innovation triggered the emergence and development of the responsible research and innovation (RRI) concept among policymakers and academics. Engaging stakeholders in the early phases of innovation processes has been identified as a major driver of inclusive, responsible, and sustainable development. Firms however have often adopted practices entirely opposite to those being advocated within the RRI framework, namely, reducing external interaction with stakeholders, focusing on exclusive communication with the scientific community and legal authorities while avoiding the social spotlight. We illustrate these practices, their causes and consequences using the case of the Aquadvantage salmon, the first genetically modified (GM) animal approved to petition for the United States (US) Food and Drug Administration (FDA) approval for human consumption. We find that such practices heighten the risk of social backlash, being undesirable from the perspective of both the organizations involved and society at large. Stakeholder engagement remains necessary in order to gain the minimum social acceptance required for contentious innovative products to enter the market. However, stakeholder engagement must be selective, focused on pragmatic organizations whose aims and interests are sufficiently broad to potentially align with corporate interests. Strategic stakeholder engagement offers a meeting point between the transformative aspirations of RRI framework proponents and legitimate business interests.
